- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07845344
Combined Analysis of Retrospective and Prospective Data From Patients Who Underwent Facet Arthroplasty With the TOPS™ System or the TOPS + Versalink™ Fixation System at a Single Center. (TOPS)
The TOPS™ system is an alternative to spinal fusion designed to stabilize-rather than fuse-the affected vertebral level, thereby relieving pain caused by degenerative spondylolisthesis and spinal stenosis. Degenerative spondylolisthesis involves abnormal, excessive vertebral movement, resulting in lower back and leg pain.
Spinal stenosis is a condition in which nerve compression causes symptoms such as pain, numbness, and tingling in the legs. The TOPS system is intended to provide stabilization for skeletally mature patients with single-level disease (L3-L5) who have not achieved sufficient symptom relief through prior conservative care. The Total Posterior Spine System ("TOPS™ system") received CE marking and has been commercially available since 2012; it also received US FDA approval in June 2023.
The Versalink™ fixation system is a bilateral titanium lumbar fusion system designed for use with a titanium cross-link as a standalone fusion device. It is also designed to connect above or below the TOPS™ device to form a hybrid construct.
The TOPS system is designed to restore lumbar spine stability while allowing for spinal canal decompression (laminectomy/facetectomy).
By using the TOPS™ system, the surgeon can remove pathological bony elements and implant a posterior spine replacement technology that effectively recreates load-bearing dynamics and spinal biomechanics, thereby preserving mobility in the treated segment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Marie-Hélène Barba
- Email: mh.barba@ecten.eu
Study Contact Backup
- Name: Jean-François Oudet
- Phone Number: 0033683346567
- Email: jf.oudet@ecten.eu
Study Locations
-
-
-
Cornebarrieu, France, 31700
- Clinique des Cèdres
-
Contact:
- Jean-Paul Lescure, Dr
- Phone Number: 0033562133369
- Email: jean-paul.lescure@orange.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Prospective and retrospective collection of data
Description
Inclusion Criteria:
- Male or female patient aged over 18 years,
- All consecutively treated patients who underwent facet arthroplasty using the TOPS™ system or the TOPS™ system + VersaLink™ system at a single center, and for whom the surgery was performed at least 6 months prior to the start of data collection,
- Patient who has received written information and has not objected to participating in the study,
- Patient capable of understanding the study and answering the Zurich Claudication Questionnaire,
- Patient affiliated with or a beneficiary of a social security scheme.
Exclusion Criteria:
- Minor patient,
- Patient treated consecutively who received the TOPS™ system or the TOPS™ system + Versalink™ fixation system at multiple surgical centers,
- Patient refusal to participate in the study,
- Protected patient: adult under guardianship, curatorship, or other legal protection; deprived of liberty by judicial or administrative decision,
- Pregnant, breastfeeding, or recently delivered woman.
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: OTHER
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Facet arthroplasty with the TOPS™ system or the TOPS™ system + Versa-link™ system
prospective and retrospective collect data |
Zurich claudication questionnaire : The Zurich Claudication Questionnaire quantifies severity of symptoms, physical function characteristics, and patient's satisfaction after treatment. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient satisfaction
Time Frame: 6 months
|
Patient satisfaction will be assessed by administering the patient satisfaction scale of the Zurich Claudication Questionnaire at the final follow-up visit. Each patient's satisfaction threshold will be defined as a raw score of 2.5 or lower on the ZCQ patient satisfaction scale. |
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Spinal Diseases
- Spinal Stenosis
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Surveys and Questionnaires
Other Study ID Numbers
- 2025-A00427-42
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.